Incyte Corporation attracted significant institutional investment according to filings released on August 27, 2026. These second-quarter transactions reflect confidence in the biopharmaceutical company’s pipeline.
Legal & General Group Plc acquired 1.6 million shares. This position is valued at approximately $182 million. Canadian pension fund Caisse de depot et placement du Quebec purchased over 1.37 million shares. This investment totals roughly $155.4 million.
H.C. Wainwright reiterated a Buy rating for the stock. The analyst set a price target of $150. This outlook follows positive data from an experimental cancer treatment.